Roche picks outsider as new CFO, as Hunziker retires
Swiss drug major Roche (ROG: VX) has appointed Alan Hippe - a newcomer to the pharmaceutical sector - to succeed Erich Hunziker - who, aged 58, has decided to retire - as chief financial officer of the company.
Mr Hippe will join Roche as a member of the corporate executive committee as of April 2011. He served as a member of the executive board of Continental AG from 2002 to 2009. Since April 2009 he has been CFO and a member of the executive board of Germany’s largest steel maker ThyssenKrupp AG.
Mr Hunziker has chosen to retire from Roche at the end of March 2011 and plans to focus on a number of board memberships. He was appointed CFO and member of the corporate executive committee in 2001, becoming deputy head of that committee in 2005. In 2010 he also assumed the role of chief information officer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze